Covalon Technologies (COV) Stock Overview
Engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
COV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Covalon Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.43 |
| 52 Week High | CA$4.30 |
| 52 Week Low | CA$2.06 |
| Beta | 0.21 |
| 1 Month Change | -7.60% |
| 3 Month Change | -13.21% |
| 1 Year Change | -22.86% |
| 3 Year Change | -3.19% |
| 5 Year Change | 104.20% |
| Change since IPO | -19.00% |
Recent News & Updates
Recent updates
Covalon Technologies Ltd.'s (CVE:COV) Popularity With Investors Is Under Threat From Overpricing
Aug 20
Some Shareholders Feeling Restless Over Covalon Technologies Ltd.'s (CVE:COV) P/S Ratio
Feb 26Subdued Growth No Barrier To Covalon Technologies Ltd. (CVE:COV) With Shares Advancing 29%
Nov 17Covalon Technologies Ltd.'s (CVE:COV) 25% Share Price Surge Not Quite Adding Up
Aug 18We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth
Aug 10Optimistic Investors Push Covalon Technologies Ltd. (CVE:COV) Shares Up 83% But Growth Is Lacking
Jun 16Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth Plans
May 01Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Feb 17Insufficient Growth At Covalon Technologies Ltd. (CVE:COV) Hampers Share Price
Dec 22We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth
Sep 02We Think Covalon Technologies (CVE:COV) Needs To Drive Business Growth Carefully
May 26Is Covalon Technologies (CVE:COV) Using Too Much Debt?
Apr 29Covalon Technologies (CVE:COV) Is Making Moderate Use Of Debt
Dec 29Shareholder Returns
| COV | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -7.6% | -0.3% | 1.6% |
| 1Y | -22.9% | 12.0% | 18.3% |
Return vs Industry: COV underperformed the Canadian Biotechs industry which returned 12% over the past year.
Return vs Market: COV underperformed the Canadian Market which returned 18.3% over the past year.
Price Volatility
| COV volatility | |
|---|---|
| COV Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: COV has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: COV's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Brent Ashton | www.covalon.com |
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device.
Covalon Technologies Ltd. Fundamentals Summary
| COV fundamental statistics | |
|---|---|
| Market cap | CA$64.16m |
| Earnings (TTM) | CA$2.31m |
| Revenue (TTM) | CA$32.99m |
Is COV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COV income statement (TTM) | |
|---|---|
| Revenue | CA$32.99m |
| Cost of Revenue | CA$14.62m |
| Gross Profit | CA$18.37m |
| Other Expenses | CA$16.06m |
| Earnings | CA$2.31m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.084 |
| Gross Margin | 55.68% |
| Net Profit Margin | 7.01% |
| Debt/Equity Ratio | 0% |
How did COV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/25 22:14 |
| End of Day Share Price | 2025/08/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Covalon Technologies Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andre Uddin | Research Capital Corporation |